Data Room for Pharmaceutical Distribution: Catalogues, Price Lists & Dossiers (2026)

Last updated: July 2026

I'm Sean Yu, co-founder of Peony, a data room company. Most of the businesses I talk to treat their product catalogue as a marketing asset — something to make pretty, put on the website, and push to as many people as possible. Pharmaceutical distribution is the one vertical where that instinct is not just wrong but potentially unlawful.

In most industries a product catalogue is marketing. In pharmaceutical distribution, the catalogue is a controlled document — because the law says prescription-only medicines may not be advertised to the public, and because the price list is the margin, printed. The same PDF that would sit happily on any other company's homepage becomes, for a licensed pharmaceutical wholesaler, a document that has to be gated, verified, version-managed, and access-logged. Get that wrong and you are looking at a regulatory problem on one side and a commercial one on the other.

This guide is written for two people. The first is a director at a licensed pharma wholesaler — MHRA-licensed, working to Good Distribution Practice, often family-run, five to fifty staff, supplying community pharmacies, veterinary practices, and hospitals. The second is an export manager at a manufacturer sending product dossiers and certificates to overseas distributors. Different jobs, same underlying problem: a body of confidential trade documents that must reach the right buyers and no one else, with proof of who saw what.

Quick answer: In the UK, a prescription-only medicine catalogue cannot lawfully be advertised to the public (Human Medicines Regulations 2012, Reg 284), but the same catalogue is permitted inside a channel directed at health professionals (Reg 294) — so it must be gated to verified trade buyers. The confidential set is your catalogue of POM lines, per-account price lists, specials line-listings, batch certificates of analysis, and credit terms (SPCs are public on the emc; their problem is version currency, not secrecy). A Peony data room (free, $0) handles this with visitor groups for per-account price isolation, update-links so customers always see the current version, dynamic watermarking to trace leaks, an NDA gate before dossier access, and an access log that maps onto GDP documentation-control expectations — priced per admin, with your trade accounts free. Peony does not verify licences for you; verification stays your process, and the room enforces and records your decision.

Where this post sits. This is the commercial distribution layer — catalogues, price lists, dossiers, and trade accounts. It is deliberately not the other pharma rooms: if you are raising money or protecting R&D and IP, read the Biotech Data Room Guide; for M&A diligence, Biotech M&A Data Room; to choose an advisor, Best Healthcare M&A Advisors; for trial documents, Clinical Research solutions. For the general how-to that applies to any industry, see the horizontal sibling: Share Price Lists and Product Catalogs Securely. This post is the pharma-specific version of that job.

Why does a pharmaceutical catalogue have to be gated when a normal one doesn't?

Because advertising a prescription-only medicine to the public is a criminal offence, and a public catalogue that promotes supply can count as advertising.

The controlling rule in the UK is the Human Medicines Regulations 2012. Regulation 284 states that a person may not publish an advertisement that is likely to lead to the use of a prescription-only medicine. The word doing the work is "advertisement": it is defined broadly enough to catch anything designed to promote the prescription, supply, sale, or use of a medicine. A catalogue of POM lines sitting on an open website, with names, pack sizes, and an invitation to order, is the sort of thing that gets caught. Breach is enforced by the MHRA and can carry an unlimited fine and up to two years' imprisonment.

But the same Regulations give you the other half of the answer. Regulation 294 permits advertising that is directed at persons qualified to prescribe or supply — health professionals — provided it carries the required particulars. That is the crux of the whole thing:

The same catalogue that is illegal on your homepage is lawful inside a gated, verified trade channel. The document does not change. The audience does. Public equals prohibited; verified health professionals equals permitted. So the gate is not a nice-to-have security feature bolted onto a marketing asset — it is the mechanism that makes the catalogue lawful at all.

This is exactly why, when you look at how UK pharma and veterinary wholesalers actually operate, none of them publish price lists or POM catalogues openly. Trade sites sit behind "apply for a trade account" walls or login-gated storefronts. That is not commercial coyness; it is a legal necessity flowing from Reg 284.

A note on framing, because it matters and I am not your lawyer: everything in this post about the Regulations is general information, not legal advice. The rules have edges and exceptions, and enforcement turns on specifics. Confirm the current position for your business with your compliance lead or counsel before you rely on it.

What about veterinary medicines — do the same rules apply?

Broadly yes, through a parallel regime, and with one wrinkle that explains why a vet-supply wholesaler carries human medicines at all.

Veterinary prescription medicines are governed by the Veterinary Medicines Regulations 2013. Advertising a POM-V product to the general public is prohibited; POM-V advertising may only be directed at vets, pharmacists, registered veterinary nurses, and professional keepers of animals. There is a stricter carve-out worth knowing: antibiotic veterinary medicines cannot be advertised even to professional keepers — the audience for those is tighter still. The upshot is the same as on the human side: a veterinary catalogue of POM-V lines belongs behind a gate that verifies the viewer is a qualified professional.

One caveat on freshness. The veterinary medicines framework has been under active reform through the 2024-26 period, so treat the specifics as the rules stand in mid-2026 and re-check the current position rather than assuming they are frozen. The direction of travel does not change the core point — POM-V lists are gated — but the detail around who counts and what particulars are required is the sort of thing that moves.

Why does a veterinary wholesaler stock human medicines?

The answer is the veterinary cascade, and it is the reason a vet-supply wholesaler's whole catalogue rides POM-style restrictions.

When there is no suitable authorised veterinary medicine for a condition, a vet may prescribe down a defined sequence — the cascade — which, at the appropriate step, allows a UK-authorised human medicine to be used. That is why veterinary practices routinely buy human medicines, and why a wholesaler serving vets ends up carrying both human and veterinary lines side by side in one catalogue. Cascade-prescribed products may not be advertised to the public either. So the wholesaler is not running two catalogues under two rulebooks; it is running one catalogue where essentially every line is a gated, trade-only item. The archetype here — a family-run, MHRA-and-VMD-licensed wholesaler supplying veterinary practices with a mix of human and veterinary medicines — is common precisely because the cascade makes that dual stock necessary.

What about specials and unlicensed lists?

Unlicensed medicines — "specials" — carry their own advertising limit that shapes how their price lists can look.

Under MHRA guidance, a specials price list may be a basic line-listing only: reference number, product name, dosage form, strength, pack size, and price. It may not carry product claims. So when you put a specials list into a gated room, the discipline is not just who sees it but what it says — a plain listing, no marketing language. This is another reason the "make the catalogue attractive" instinct backfires in pharma: for specials, the law wants the listing bare.

What does GDP expect for document control, and how does a room help?

Good Distribution Practice expects your documentation to be controlled, version-managed, and auditable, with records kept for years — and an access-logged room maps onto that pattern, though it is not a compliance product.

Let me be precise about the expectations, because vagueness here helps nobody. UK GDP expects controlled, auditable documentation under proper version management. Transaction records must be kept for at least five years — or one year past the product's expiry date, whichever is longer (five years, not the seven that people sometimes assume). In an incident, you should be able to demonstrate chain of custody within 24 hours. Documents that are superseded should be managed so the current version is the one in use.

Here is how a controlled sharing layer lines up with that:

• Version management — documents live behind stable links, and replacing the file behind a link retires the old version without breaking the address, so the current version is what opens.
• Auditable access — every view and download is logged, so "who accessed which document, and when" is answerable rather than reconstructed from memory.
• Scoped access — each account reaches only its own materials, which is cleaner to defend than a broad shared drive.
• Retention — records and access logs persist across the retention window instead of scattering across inboxes.

Now the honest boundary, because I have seen vendors get this dangerously wrong. No software is "GDP-certified," and no tool makes you compliant. Compliance is your quality system, your people, and your processes. What a room like Peony does is support the documentation-control pattern GDP expects: it gives you version discipline and an audit trail. When an inspector asks how you know a customer had the current certificate, or who accessed a given document, an access log is a far better answer than a shrug at a shared folder. That is a genuine benefit — and it is a different claim from "this makes you compliant," which would be false.

Why is the price list the real secret in pharma distribution?

Because in this industry the published price is public and the discount is not — the margin is the secret, and it lives account by account.

Take the NHS Drug Tariff. The reimbursement list prices in it are public information. What is not public is the wholesale acquisition price and the discount off list that a given account has negotiated — that spread is the wholesaler's margin, and it is closely held. Historically, under older pricing mechanics, you might see something like a low-double-digit percentage off list from manufacturer to wholesaler and a slightly smaller discount on to the pharmacy, leaving a couple of points of spread as margin — but treat those numbers as directional and dated, not current, because the mechanics have moved. The structural point survives: the list is public, the discount is the secret.

That secret is fragile in a specific way. Per-account and tiered pricing is the norm in this trade. Buying groups negotiate collective discounts on behalf of their members; independent pharmacies and practices negotiate their own; a large hospital account is different again. When one account's terms leak to another, or to a competitor, two things happen at once: you get disputes with the account that feels short-changed, and you get an eroded negotiating position because your floor is now visible. There is no famous UK case of a wholesaler price list leaking to a competitor that I can point to — and I am not going to invent one — but the incentive structure is the whole story, and it is why every serious operator isolates pricing per account.

What does a price leak actually cost in pharmaceutical distribution?

More than in most industries, because leaked pharma prices propagate through mechanisms unique to this sector.

• International reference pricing. More than 75 countries use international or external reference pricing, where a medicine's price in one market is benchmarked against its price in others. A low price that leaks in one country can become the benchmark that drags down reimbursed prices elsewhere. This is not hypothetical mechanics — Germany's 2024 reform introduced confidential reimbursement prices specifically to blunt this reference effect. So a leak is not a local embarrassment; it can travel across borders through the reference machinery.
• Parallel trade. Price gaps between EU markets create arbitrage, and studies attribute meaningful price erosion to it — one health-economics estimate puts the reduction in manufacturer prices from parallel imports in the region of 12 to 19 percent (treat as an academic estimate, not a universal constant). Visible price differences are the fuel for that trade.
• Tender secrecy. Awarded tender prices are generally confidential, and for good reason: a leaked bid hands your next tender to a competitor who now knows exactly what to undercut.

Put those together and you can see why "share the catalogue and the price list carefully" is not paranoia in pharma. The downside of a leak compounds through reference pricing, parallel trade, and tenders in ways it simply does not for, say, industrial fasteners. I have hedged the figures above deliberately — the exact numbers vary by study and market — but the direction is not in doubt.

How does the dossier flow work for an exporter, and where does it leak?

An exporter ships a structured technical dossier and a stream of certificates to distributors abroad, and the leak point is the same as always — the moment it lands in an inbox.

The core artefact is the CTD dossier — the Common Technical Document — organised into five modules: Module 1 regional administrative information, Module 2 summaries, Module 3 quality (including stability data), Module 4 nonclinical data, and Module 5 clinical data. In electronic form it is wrapped as an eCTD. Alongside the dossier, a distributor evaluating your product will expect a certificate of analysis per batch, GMP or WHO-GMP certificates, stability data, and version-locked artwork and labelling. Central to registration in many markets is the Certificate of a Pharmaceutical Product — the WHO-format CPP issued by the exporting country's regulator, which is required for registration in more than 80 countries. Losing control of any of these is losing control of your competitive position in a market you have not entered yet.

How does the industry itself split who sees what?

Through the Drug Master File open/closed structure, which is the cleanest real-world model of tiered document access I know.

A DMF (or ASMF in the EU) has two parts. The open part — the applicant's part — is shared with the customer under a confidential disclosure agreement. The closed, restricted part — the manufacturer's proprietary know-how — goes only to the regulator, never to the customer. When a customer needs the regulator to consider that closed part for their own application, the DMF holder issues a Letter of Access authorising the regulator to read it for that specific submission. One DMF, many Letters of Access, and a hard wall between what the customer sees and what only the regulator sees.

That is precisely the shape your sharing layer should enforce. Your who-may-see-what tiering should mirror the DMF split: some documents open to a qualified counterparty under NDA, some never leaving your control, access granted per counterparty and per purpose. The industry already thinks in these tiers; the tooling should too, instead of collapsing everything into an email thread where "open part" and "everything else" get forwarded together.

What are exporters using today, and why is it a problem?

Mostly email and messaging apps for the actual documents, and marketplaces for discovery — and the two rarely meet.

The honest picture: primary dossier and certificate exchange still happens over email and WhatsApp attachments, with bulk transfers occasionally going through general file-sharing tools (that last part is inferred general practice, not a measured statistic). Then there are the marketplaces — Pharmaoffer, PipelinePharma, and others — which are genuinely useful as discovery layers where manufacturers and buyers find each other. Pharmaoffer describes a base of several thousand GMP-verified manufacturers across 200-plus countries; PipelinePharma advertises large catalogues of products and CTD dossiers. I am hedging those counts deliberately because they are vendor-stated, not independently audited. And critically, even for buyers introduced on a marketplace, the actual dossier exchange still tends to move off-platform onto email. Discovery is solved; controlled exchange is not.

The risk in that gap is not abstract. Third-party custodians get breached: the Cencora breach disclosed in February 2024 exposed data connected to a number of drugmakers through a single intermediary. Every time a dossier lands in an inbox or on a general drive, you have added a custodian you do not control to the chain. A gated link that you own — watermarked, revocable, logged — is the missing controlled layer between "we found each other" and "here is our confidential technical package."

Which pharma documents are public, which are trade-gated, and which never leave the regulator?

This is the map that resolves most of the confusion, so it is worth setting out plainly. There are three tiers, and treating a document as more or less secret than it actually is causes real problems.

Public — freely available, do not pretend otherwise:

• Summaries of Product Characteristics (SPCs/SmPCs) are public and free on the electronic Medicines Compendium. Never frame an SPC as confidential. The pain with SPCs is not secrecy; it is version currency — making sure the customer is looking at the current SPC and not an old saved copy.
• Safety Data Sheets (SDS) are public by law.

Trade-gated — lawful to share within the verified trade channel, not to the public:

• Your catalogue and availability of POM / POM-V lines.
• Per-account price lists and negotiated discounts.
• Specials line-listings (bare listing, no claims).
• Batch certificates of analysis (batch- and customer-specific).
• Credit terms, and quality or technical agreements.

Regulator-only — never goes to the customer:

• The closed part of the Drug Master File — the manufacturer's protected know-how, released to the customer's regulator only via a Letter of Access.

The practical instruction that falls out of this map: do not gate what is public, and do not leak what is regulator-only. Point customers at the emc for SPCs and spend your control effort on the trade-gated tier, where the whole game is who sees which catalogue, which price, and which version. That is the tier a data room is for.

Which controls actually map to the pharma distribution job?

Here is the answer-first mapping — the specific problem, then the control that addresses it. This is the part of the post I would keep if you kept nothing else.

• Per-account price isolation — use visitor groups. Each account or tier is its own group with its own price list attached; accounts cannot see each other. Add a group NDA and pre-qualification questions and you have a trade-buyer verification workflow. Honest boundary: Peony does not itself verify licences. Your team checks the register and reviews the licence; the room enforces and records the decision you made.
• Always the current version — use update-links. Swap the SPC, certificate, or price list behind the link and every recipient now opens the live version. This is the fix for stale versions circulating.
• Trace a leak to an account — use dynamic watermarking. Each price list or dossier carries the viewer's identity and timestamp, so a leaked copy points back to the account it came from.
• Access that ends with the agreement — use link-expiry and revoke-access. Set an expiry to match the contract term, or revoke on the day an agreement ends, and the catalogue, prices, and dossiers go dark at once.
• Know who actually engaged — use page-analytics. See which distributor read the dossier and which pages they lingered on. A bidder who stops engaging is telling you something.
• CDA before the dossier — use the NDA gate. Access to the dossier is conditional on accepting the confidentiality agreement, mirroring the DMF open-part-under-CDA convention.
• Bring documents in, not just push them out — use file-collection. Prospective accounts submit applications, credit forms, and licence evidence through a link without needing an account.
• Organise thousands of lines — use auto-indexing. A catalogue of 500 to 5,000 lines plus batch certificates gets sorted into a browsable structure automatically.
• Your trade portal, your name — use a custom domain and branding so the gated channel looks like your business, not a generic file link.

One boundary on e-signatures worth stating clearly. E-signature is perfectly appropriate for distribution agreements and trade-account contracts — sign them electronically and move on. But UK controlled-drug requisitions still require wet-ink signatures: the Home Office has confirmed that electronic signatures are not acceptable for Schedule 2 and 3 controlled-drug requisitions. So do not let anyone tell you e-sign covers your CD requisitions — it does not, and that is a legal line, not a product limitation.

Doesn't SharePoint, Dropbox, or an ordering portal already do this?

Each does part of the job and misses the part that matters for confidential pharma distribution. Here is the honest comparison, including where a data room is the wrong tool.

SharePoint / Dropbox / Google Drive. These are excellent for internal collaboration, and if your team is co-editing SOPs, keep using them. What they lack is per-account external gating discipline: no native way to give 300 accounts 300 different price lists, no per-viewer watermarking, no trade-buyer verification workflow. And there is an inspection dimension — I would frame this as an inspector expectation rather than a quote from any regulation — a broadly shared folder tends to read as a red flag in a GDP documentation review, because it is hard to show controlled, scoped, version-managed access from a folder that has been shared around. For confidential external distribution, a sync tool is the wrong shape.

Ordering portals and e-commerce storefronts. These transact — they take orders, run baskets, handle checkout. I will concede the obvious: you need one of these for orders, and a data room does not replace it. Login-gated storefronts are common in this trade for exactly that reason. But an ordering portal is not built for confidential, tracked document exchange — watermarked dossiers, per-account price-list isolation, revocable dossier access, engagement analytics. The two sit alongside each other: the storefront takes the order; the data room handles the confidential document layer around it.

Deal-based virtual data rooms (Datasite, iDeals, and similar). These are strong products — for what they are built for, which is M&A projects. They are designed and priced around a transaction: a defined deal, a set of bidders, a diligence window, then the room closes. Pharmaceutical trade distribution is not a project; it is always-on — you are sharing catalogues, prices, and certificates with a live book of accounts year-round. Paying deal-VDR project pricing to run a permanent trade channel is paying for the wrong shape.

Where Peony fits. Peony is built for the always-on case and priced for it: per admin seat, with recipients free. That last part is decisive when you have between 100 and 1,000 trade accounts — per-user pricing punishes exactly the thing a wholesale book is made of, lots of external recipients. Peony is not an ordering system and it is not a licence-verification service; it is the controlled document layer that gates, versions, watermarks, and logs. That is a narrower claim than "it does everything," and it is the true one.

What does it cost, and is it worth it for a small wholesaler?

It starts free, and the pricing model is the point — you pay for admins, not for the trade buyers on the other side of the link.

Peony's plans:

• Free — $0. A real starting point, not a two-week trial.
• Business — $30 per admin per month (annual billing).
• Data Room — $52 per admin per month (annual billing), adding dynamic watermarking and unlimited rooms — the tier most distribution setups want, because watermarking is what makes leaks traceable.

The number that decides this for a wholesaler is not the headline price; it is the per-admin model with free recipients. Your internal admins hold the seats. Your trade accounts — whether you have 100 or 1,000 — open their catalogues and price lists for free. A per-user platform would bill you for every external account, which is precisely the wrong incentive when your business is having many accounts. That difference is why 5,900+ customers run controlled sharing on Peony without their bill scaling with their audience.

I run Peony, a data room company, and I would rather tell you plainly where it stops than oversell it. Peony gates, versions, watermarks, tracks, and logs — and its per-admin, free-recipient pricing is built for the shape of a trade book, which is the honest reason a family-run wholesaler can run this properly without enterprise money. It does not take your orders (keep your storefront), it does not verify your customers' licences (that stays your process against the register), and it does not make you GDP-compliant (that is your quality system) — it supports the documentation-control pattern GDP expects. Being clear about those boundaries is exactly why the 5,900+ customers who use it know what job it is doing. If that is the job you have — a controlled, always-on channel for pharmaceutical catalogues, price lists, and dossiers — it is built for you.

Frequently asked questions

Can we legally put our prescription-only medicine catalogue on our public website, or does it have to be gated?

In the UK you generally cannot. The Human Medicines Regulations 2012, Regulation 284, prohibit publishing an advertisement likely to lead to the use of a prescription-only medicine, and "advertisement" is defined broadly enough to catch a public catalogue that promotes supply. Regulation 294 permits advertising directed at health professionals qualified to prescribe or supply. So the same catalogue that is unlawful on your open homepage is lawful inside a gated channel restricted to verified trade buyers. Veterinary POM-V lists follow the same logic under the Veterinary Medicines Regulations 2013. A gated data room keeps the catalogue behind verification and logs who accessed it. This is not legal advice; confirm the current position with your compliance lead or counsel.

How do we gate our catalogue so only verified trade buyers — licensed pharmacies and vet practices — can see it?

You separate two jobs: verification, which is your decision, and enforcement, which the room handles. Your team checks the applicant against the relevant register and reviews their licence — Peony does not verify licences or run KYC for you. Once you have made that call, you use visitor groups so a buyer only reaches the catalogue after they are placed in an approved group, and you put an NDA or trade-account agreement gate in front of access. New applicants can submit their details and licence evidence through a file-collection link without needing an account. The register check stays your process; the room enforces the decision and records it.

How do we give each trade account its own price list so accounts can't see each other's pricing?

Use visitor groups. Each account, or each pricing tier, becomes its own group, and you attach only that group's price list to that group. A buying group on a collective discount never sees the terms of an independent pharmacy, and neither sees the other. When you revise pricing, you swap the file behind an update-link so the group always opens the current version rather than a stale PDF someone saved months ago. Because Peony prices per admin seat and recipients are free, giving hundreds of accounts their own isolated view does not multiply your bill. The list price may be public via the Drug Tariff; the discount is the secret, and this is how you keep it account-by-account.

Our per-account pricing keeps reaching competitors — how do we trace the leak and stop it?

Two controls work together. Dynamic watermarking stamps each price list with the viewer's identity and a timestamp, so a screenshot or forwarded PDF carries the account it came from — you can trace a leaked list back to the account that opened it. Page-analytics show you who opened what and when, which surfaces unusual access before it becomes a pattern. Neither makes a leak physically impossible, but together they convert an anonymous leak into an attributable one, which changes behaviour and gives you evidence for the account conversation. Pair that with a signed confidentiality clause in the trade-account agreement so the obligation is on record. The point is deterrence and attribution, not a promise that nothing can ever be copied.

How do we stop out-of-date SPCs and CoAs circulating to customers after a revision?

Stop sending files as attachments and start sending links. With an update-link, the recipient bookmarks or saves a single URL, and when you replace the document behind it — a revised certificate of analysis, a superseded price list, an updated technical sheet — everyone opening that link now sees the current version. Summaries of product characteristics themselves are public and free on the electronic Medicines Compendium, so the problem is rarely secrecy; it is version currency, making sure the copy a customer relies on is the live one and not a PDF from two revisions ago. A link you control solves that. An email attachment, once sent, is frozen and uncontrollable, and every forward compounds the drift.

What's the cleanest way to organise batch-level certificates of analysis so buyers always find the right batch?

Group certificates of analysis by product line first, then by batch number within each line, so a buyer navigates product then batch rather than scrolling one flat pile. Peony's AI auto-indexing sorts a bulk upload of hundreds or thousands of certificates into a browsable structure, which matters when a single line carries dozens of batches. Give each trade account access through its visitor group, and use update-links so a re-issued certificate replaces the old one at the same address. The goal is that a hospital pharmacist or vet chasing the paperwork for one specific batch reaches it in a couple of clicks, with the current version guaranteed, instead of emailing you to ask which file is the right one.

What does an MHRA GDP inspector expect to see for document control — and how do we prove who accessed what?

Good Distribution Practice expects controlled, version-managed, auditable documentation, with transaction records kept at least five years — or one year past expiry, whichever is longer — and chain of custody demonstrable within 24 hours during an incident. An access-logged room maps onto that documentation-control pattern: every view and download is recorded, versions are managed behind stable links, and access is scoped per account. To be clear, no software is "GDP-certified" and no tool makes you compliant on its own — compliance is your quality system. But an audit trail that shows who accessed which document, and when, is exactly the kind of evidence that supports a document-control conversation with an inspector, rather than pointing at a shared drive nobody can reconstruct.

How do we stop a product dossier being forwarded beyond the confidentiality agreement?

You gate the dossier behind an NDA or confidential disclosure agreement so access is conditional on acceptance, then you use controls that survive the send. Dynamic watermarking marks each dossier with the recipient's identity so a forwarded copy is traceable. Link-expiry and revoke-access let you cut access the moment a talk stalls or an agreement lapses. Page-analytics tell you whether the distributor actually read it — a bidder who stops engaging is telling you something. The industry already thinks this way: a Drug Master File has an open part shared under CDA and a closed part only the regulator sees, released for a specific application via a Letter of Access. Your sharing layer should enforce that same who-may-see-what tiering rather than trusting an email chain.

How do we revoke a distributor's access to dossiers and price lists the day the agreement ends?

With links you control, revocation is immediate rather than aspirational. When a distribution agreement ends, you revoke the distributor's access or let a pre-set link-expiry date do it automatically, and their group loses the catalogue, the price list, and any dossiers at once. Compare that with email: everything you ever attached is still in their inbox on the last day of the contract, and there is no recall. Page-analytics give you a record of what they accessed during the relationship, which matters if there is a later dispute about what was shared. Set expiry dates to match contract terms when you create the link, so lapsed agreements close themselves even if the renewal paperwork slips. Access should track the agreement, not outlive it.

Is a data room overkill for a family-run wholesaler with 500 product lines — wouldn't SharePoint or Dropbox do?

SharePoint and Dropbox are built for internal collaboration, not for gating a catalogue to hundreds of external trade accounts with different prices each. They have no native per-account price isolation, no per-viewer watermarking, and no trade-buyer verification workflow, and a broadly shared folder is the kind of thing an inspector reads as weak document control. For 500 lines and a book of trade accounts, the job is not storage; it is controlled external distribution — who sees which catalogue, which price, which version, and proof of it. That is what a data room does and a file-sync tool does not. Peony starts free and is priced per admin, with recipients free, so a small wholesaler is not paying enterprise money to run this properly.

We're a pharma exporter sending dossiers and CoAs to overseas distributors — is email really that risky?

Email is fine for a quote and risky for a dossier. Once you attach a CTD module or a certificate of analysis, you lose control: it can be forwarded past your CDA, it sits permanently in inboxes you cannot reach, and you have no idea whether the distributor read it or shelved it. Third-party custodian risk is real too — the Cencora breach in February 2024 exposed data tied to a number of drugmakers through one intermediary. A gated link keeps the dossier behind an NDA, watermarks it to the recipient, lets you revoke it when talks end, and shows you engagement through page-analytics. Marketplaces such as Pharmaoffer and PipelinePharma help you get discovered, but the actual dossier exchange still tends to happen over email — which is exactly the gap a controlled link closes.

How much does a data room cost for a small pharmaceutical wholesaler with hundreds of trade accounts?

Peony is free to start at $0. The Business plan is $30 per admin per month and the Data Room plan, which adds dynamic watermarking and unlimited rooms, is $52 per admin per month on annual billing. The detail that matters for distribution is per-admin pricing: you pay for your internal admin seats, and your trade buyers — whether 100 accounts or 1,000 — access their catalogues and price lists for free. Per-user platforms punish you for having many external recipients, which is exactly the shape of a wholesale book. Deal-based virtual data rooms are built and priced for one-off M&A projects, not always-on trade distribution running year-round. For a family-run wholesaler, the economics of per-admin plus free recipients are what make this affordable at scale.

I'm the finance lead at a family-run wholesaler — how do I justify a data room to the owners?

Price the failure, not the tool. The exposures a gated room removes are the expensive ones: a per-account discount leaking into the trade (margin repriced across the book), a GDP documentation finding (remediation, re-inspection, management time), and a dossier travelling beyond its confidentiality agreement. Against that, the tooling cost is bounded by your admin count — Peony runs $30-$52 per admin per month with trade accounts free, so the bill does not scale whether you serve 100 or 1,000 buyers. Two finance-native bonuses: the access log doubles as inspection-ready documentation-control evidence, and version-controlled links kill the stale-price disputes that land on finance's desk as credit notes. Bounded cost, unbounded exposures removed, evidence generated as a by-product.

Related resources

• Share Price Lists and Product Catalogs Securely — the horizontal how-to sibling this pharma guide is built on
• Biotech Data Room Guide — R&D, IP, and fundraising rooms
• Collect Documents From Clients Securely — run account applications and credit forms inbound
• E-Sign Customer Agreements at Scale — distribution and trade-account contracts (not CD requisitions)
• What Is a Virtual Data Room? — the foundational explainer
• Virtual Data Room Cost Guide — how VDR pricing models compare
• Pharma solutions — the pharmaceutical distribution solution page
• Digital Catalog Software vs Data Room — if you are weighing catalog tools against a gated room for the trade catalogue
• Biotech solutions — the life-sciences R&D solution page
• Clinical Research solutions — trial and study documents
• Logistics solutions — distribution and supply-chain document control
• Visitor Groups — per-account price isolation and group NDAs
• Update Links — recipients always open the current version
• NDA Gate — confidentiality acceptance before dossier access